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Abstract
Intrinsic antiviral resistance represents the first line of intracellular defence against virus infection. During herpes simplex
virus type-1 (HSV-1) infection this response can lead to the repression of viral gene expression but is counteracted by the
viral ubiquitin ligase ICP0. Here we address the mechanisms by which ICP0 overcomes this antiviral response. We report that
ICP0 induces the widespread proteasome-dependent degradation of SUMO-conjugated proteins during infection and has
properties related to those of cellular SUMO-targeted ubiquitin ligases (STUbLs). Mutation of putative SUMO interaction
motifs within ICP0 not only affects its ability to degrade SUMO conjugates, but also its capacity to stimulate HSV-1 lytic
infection and reactivation from quiescence. We demonstrate that in the absence of this viral countermeasure the SUMO
conjugation pathway plays an important role in mediating intrinsic antiviral resistance and the repression of HSV-1 infection.
Using PML as a model substrate, we found that whilst ICP0 preferentially targets SUMO-modified isoforms of PML for
degradation, it also induces the degradation of PML isoform I in a SUMO modification-independent manner. PML was
degraded by ICP0 more rapidly than the bulk of SUMO-modified proteins in general, implying that the identity of a SUMO-
modified protein, as well as the presence of SUMO modification, is involved in ICP0 targeting. We conclude that ICP0 has
dual targeting mechanisms involving both SUMO- and substrate-dependent targeting specificities in order to counteract
intrinsic antiviral resistance to HSV-1 infection.
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Introduction
The ubiquitin pathway regulates many essential cellular
processes including protein degradation, the cell cycle, transcrip-
tion and DNA repair. It is not surprising that many viruses have
therefore evolved strategies to take advantage of this pathway in
order to enhance their replication (for a recent review see [1]).
During herpes simplex virus type-1 (HSV-1) infection, one of the
first viral proteins to be expressed is ICP0 (infected cell protein 0),
an E3 ubiquitin ligase of the RING finger class that is required for
the efficient initiation of lytic infection and productive reactivation
of viral genomes from latency (reviewed in [2]). Whilst the exact
mechanisms by which ICP0 stimulates infection remain to be
elucidated, it is clear that the ubiquitin ligase activity of ICP0 plays
a fundamental role in regulating infection. Deletion or point
mutations within the RING finger of ICP0 that inactivate its
ubiquitin conjugation activity completely impair its ability to
stimulate lytic infection and the reactivation of quiescent viral
genomes [3–8].
During infection, ICP0 localizes to promyelocytic leukemia
(PML) nuclear bodies (PML-NBs, also known as ND10 or PODs)
where it induces the proteasome-dependent degradation of PML,
its small ubiquitin-like modifier (SUMO)-modified isoforms, and
SUMO-modified Sp100 [9–11]. Recent findings suggest that these
ND10 proteins play a role in contributing to intrinsic antiviral
defence, as depletion of these proteins increases the likelihood of
an ICP0-null mutant virus entering productive infection [12,13].
The available evidence is consistent with the hypothesis that ICP0
targets specific cellular proteins for proteasome-dependent degra-
dation in order to inhibit (or relieve in the case of latency) cellular
mechanisms that would otherwise repress viral transcription [14].
However, the mechanism(s) by which ICP0 targets these cellular
proteins for degradation remains unclear.
One of the earliest detectable events during HSV-1 infection is a
cellular response that leads to the accumulation of ND10
components at sites closely associated with viral genomes soon
after they have entered the nucleus. This response is rapidly
counteracted by the ubiquitin ligase activity of ICP0, a phenotype
that correlates well with its ability to stimulate lytic infection and
reactivation from quiescence [8,15,16]. We have recently shown
that this recruitment is dependent upon SUMO Interaction Motifs
(SIMs) within these proteins and that mutation of these motifs
inhibits their abilities to repress viral replication [17]. These data
implicate a role for the SUMO conjugation pathway in mediating
intrinsic resistance to HSV-1 infection. However, several impor-
tant questions remain outstanding. For example, how does ICP0
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target PML and its SUMO-modified isoforms for degradation,
what other cellular factors are also targets for ICP0-mediated
degradation, and how does ICP0 inhibit the recruitment of
proteins other than PML to these repressive foci associated with
incoming HSV-1 genomes?
Recent findings have highlighted a link between ubiquitin ligase
targeting and the proteasome-dependent turnover of SUMO-
modified proteins through the discovery of SUMO Targeted
Ubiquitin Ligases (STUbLs). These proteins represent a class of
RING finger ubiquitin ligases that contain SIMs that were initially
identified in yeast through the characterization of Slx5 and Slx8 in
S. cerevisiae, Rfp1 and Rfp2 in Schizosaccharomyces pombe, and more
recently RNF4 in mammalian cells [18–23]. These SIM-
containing ubiquitin ligases provide a means of regulating
SUMO-modified substrates via their ubiquitination and protea-
some-dependent degradation. SIMs typically consist of a short
core of hydrophobic amino acids, (V/I/L)-x-(V/I/L)-(V/I/L) or
(V/I/L)-(V/I/L)-x-(V/I/L), which form a b-strand that binds in a
groove formed between the a-helix and a b-strand of SUMO [24–
26]. SIMs are often followed by acidic or phospho-serine residues
that enhance the SIM-SUMO interaction [27,28]. The best
characterized mammalian STUbL is RNF4, a SIM-containing
RING finger ubiquitin ligase that promotes the degradation of
SUMO-modified PML following arsenic trioxide treatment.
Multiple SIMs within the N-terminus of RNF4 mediate its
association with poly-SUMO chains anchored on PML, leading to
the ubiquitination of both SUMO and PML [22,23,29,30].
Given the parallels between the STUbL activity of RNF4 and
ICP0’s ability to degrade PML, and as ICP0 had previously been
shown to induce the loss of SUMO conjugates following ectopic
expression of tagged SUMO-1 [9], we decided to investigate if
ICP0 represented a viral STUbL. Here we report that ICP0
contains multiple SIM-like sequences (SLSs), one of which shares
homology to a SIM previously characterized within hDaxx and
HCMV IE2, and that mutation of specific SLSs inhibits its ability
to interact with and promote the ubiquitination of SUMO-2
chains. We demonstrate that during infection ICP0 induces the
global degradation of high molecular weight (MW) SUMO
conjugates in a RING finger- and proteasome-dependent manner,
although certain SUMO-conjugates are degraded more rapidly
than others. Utilizing a panel of ICP0-expressing cell lines, we
show that combined mutation of several SLSs has a clear
detrimental effect upon ICP0 function and its ability to degrade
SUMO-conjugates. Using PML as a model substrate, we
demonstrate that ICP0 preferentially induces the degradation of
all SUMO-modified PML isoforms, but can additionally target
PML isoform I for degradation in a SUMO modification-
independent manner. We also demonstrate that the SUMO
conjugation pathway plays an important role in mediating the
recruitment of ND10 components to sites associated with
incoming HSV-1 genomes. Depletion of Ubc9, the sole E2
SUMO conjugating enzyme, partially relieves this cell-mediated
repression mechanism and increases the replication efficiency of
an ICP0-null mutant virus. Taken together our data demonstrate
that the SUMO conjugation pathway contributes to intrinsic
antiviral resistance and that these activities are counteracted by
both SUMO- and substrate-dependent targeting specificities of
ICP0.
Results
The SUMO conjugation pathway plays a role in intrinsic
resistance to HSV-1
Previous studies have shown that several ND10 proteins,
namely PML, Sp100, hDaxx and ATRX, contribute to intrinsic
resistance to HSV-1 infection, and that this cellular response is
counteracted by the viral ubiquitin ligase ICP0 [12,13,31]. An
important aspect of intrinsic antiviral resistance is the ability of
these constitutively expressed proteins to relocate to sites
associated with incoming viral genomes in order to mediate the
transcriptional repression of viral gene expression [15,16,31]. We
have recently shown that mutation of SIMs within PML and
hDaxx inhibited the ability of these proteins to localize to HSV-1
genomes and thereby restrict the replication of an ICP0-null
mutant virus [17]. Furthermore, in cells depleted of PML
additional SUMO-2/3 conjugates were observed to localize to
sites associated with incoming viral genomes [17]. These data
imply a potential mechanistic role for SUMO conjugation in
mediating intrinsic antiviral resistance.
To test this hypothesis, human diploid fibroblasts (HFs) were
transduced with lentiviruses expressing control (shNeg) or anti-
Ubc9 shRNAs and analyzed in assays monitoring intrinsic
resistance to HSV-1 infection, either in the presence or absence
of ICP0 (Figures 1 and S1). Ubc9 is the sole E2 SUMO
conjugating enzyme and is essential for SUMO conjugation. Cells
stably expressing an shRNA to Ubc9 exhibited significant
depletion in Ubc9 expression, as well as decreased abundance of
SUMO-1 and SUMO-2/3 conjugates in comparison to control
cells (Figure 1A and data not shown). Ubc9-depleted cells also
showed significant reductions in SUMO modification of both
PML and Sp100 (Figure 1A), dispersal of intra-nuclear SUMO-1
and SUMO-2/3 conjugates, and dramatic changes in the number
and distribution of ND10 (Figure 1B, bottom panels). These data
demonstrate that depletion of Ubc9 efficiently restricts the SUMO
conjugation pathway, affecting the overall abundance of SUMO-
conjugates and ND10 integrity.
To investigate the role of SUMO conjugation in intrinsic
antiviral resistance we examined the relative plaque formation
efficiencies (PFE) of both wild type (wt) and ICP0-null mutant
(DICP0) HSV-1 in control and Ubc9-depleted cells. Wt HSV-1
PFE was unaffected by depletion of Ubc9 (Figure 1C). In contrast,
ICP0-null mutant (DICP0) HSV-1 infection exhibited a 10-fold
Author Summary
Viruses must evade several antiviral defences in order to
establish a productive infection. These include antibody-
and cell-mediated acquired immunity and interferon-
regulated innate immunity. Recently, a third arm of
antiviral defence has been discovered, so called intrinsic
immunity. This aspect of antiviral resistance represents the
first line of intracellular defence against virus infection and
is mediated by pre-existing cellular factors that attempt to
repress viral replication during the initial stages of
infection. Like acquired and innate immunity, viruses have
evolved mechanisms that overcome intrinsic defence. Here
we show that in response to herpes simplex virus type-1
(HSV-1) infection an important aspect of intrinsic immunity
is regulated by the small ubiquitin-like modifier (SUMO)
conjugation pathway. In response to this defence, the virus
induces rapid degradation of specific SUMO-conjugated
proteins, followed by widespread loss of SUMO-conjugat-
ed species in general. Inactivation of the SUMO pathway
inhibits the cell’s ability to efficiently repress viral
replication in the absence of this viral countermeasure.
Our data identifies an important regulatory pathway that
mediates intrinsic resistance to HSV-1 infection and
describes the biochemical mechanism that the virus
utilizes in order to counteract this antiviral defence.
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increase in PFE in Ubc9-depleted cells compared to control cells
(Figures 1C and 1D). Although significant depletion of Ubc9 was
achieved (Figure 1A), the SUMO pathway is required for cell
division [32-34]. In accordance, we noted that Ubc9 depletion
could not be maintained long-term and that depleted cells had to
be analyzed soon after isolation. Therefore, it is likely that some
Ubc9 remains in order to allow limited cell division to occur while
under selection. The observed increase in ICP0-null mutant PFE
may therefore represent an underestimate in the repressive role
that SUMO conjugation plays during HSV-1 infection in the
absence of ICP0 expression. We note that depletion of Ubc9 itself
does not impact upon the infection process per se, as wt virus was
unaffected in plaque forming efficiency in comparison to control
cells (Figure 1C).
We next investigated the recruitment of SUMO and PML to
sites associated with incoming viral genomes in the absence of
ICP0 expression (Figure S1). Viral genomes can be visualized by
the appearance of punctate foci containing the major HSV-1
transcription activator ICP4 [15], which binds strongly to viral
DNA. Infection of control cells resulted in a significant localization
of SUMO-1 and SUMO-2/3 conjugates, as well as PML, to sites
closely associated with viral genomes (Figure S1, shNeg panels). In
contrast, recruitment of PML and SUMO-conjugates was greatly
reduced in cells depleted of Ubc9 (Figure S1, shUbc9 panels). We
conclude that the SUMO conjugation pathway is required for the
efficient recruitment of intrinsic antiviral factors to sites associated
with incoming HSV-1 genomes and the efficient repression of
ICP0-null mutant replication.
Figure 1. The SUMO pathway contributes to intrinsic antiviral resistance to HSV-1 infection. (A) Western blots analyzing the expression
of Ubc9, SUMO-2/3 conjugates, PML and Sp100 in HFs stably expressing control (shNeg) or Ubc9 (shUbc9) shRNAs. (B) Nuclear distribution of
endogenous SUMO-1 and SUMO-2/3 conjugates, PML and Sp100 at ND10 in uninfected shNeg and shUbc9 cells. Scale bar represents 5 mm. (C) shNeg
or shUbc9 cells were infected with wt or ICP0-null mutant (DICP0) viruses expressing a b-galactosidase reporter gene from the tk locus. 24 hours
post-infection the cells were stained for b-galactosidase expression and relative plaque formation efficiencies calculated and expressed as fold
increase with respect to the appropriate control infection. Means and standard deviations of three independent experiments are presented. (D)
Duplicate wells of shNeg and shUbc9 cells infected with two input doses of DICP0 virus and stained for b-galactosidase expression 24 hours post-
infection.
doi:10.1371/journal.ppat.1002245.g001
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ICP0 induces the proteasome-dependent degradation of
SUMO-conjugates during infection
ICP0 has been reported to induce the proteasome-dependent
degradation of PML and its SUMO-modified isoforms [9-11], as
well as other SUMO-1 conjugated proteins following the ectopic
expression of myc-tagged SUMO-1 [9,35,36]. We therefore
decided to investigate the effect of ICP0 on the stability of
endogenous SUMO-1 and SUMO-2/3 conjugated proteins.
HSV-1 infection of HFs at a high multiplicity of infection (MOI)
of 5 plaque forming units (pfu) per cell induced a general loss of
high MW SUMO-conjugates in an ICP0-, RING finger- and
proteasome-dependent manner (Figure 2A, an independent
experiment is shown in Figure S2B). Intriguingly, instead of a
decrease, a significant increase in the levels of both SUMO-1 and
SUMO-2/3 conjugates was detected at this MOI with ICP0-null
(DICP0) and ICP0 RING finger deletion (DRING) mutant viruses
(Figure 2A). The relative infection efficiencies of the wt and
mutant viruses were compared by detection of the viral DNA
polymerase accessory factor UL42. While the mutant viruses
exhibited some defect in viral gene expression at this MOI, this
was not sufficient to explain the differences in SUMO-conjugate
expression levels during infection (Figure 2A). The C-terminus of
ICP0, encompassing its USP7 binding domain and ND10
localization sequences, was also required for efficient SUMO-
conjugate degradation (Figure S2C). This activity occurred in a
number of other cell types, including primary keratinocytes
(HaCat, data not shown) and HepaRG hepatocytes (Figure
S3A). As observed previously [19,37], addition of the proteasome
inhibitor MG132 not only inhibited ICP0-mediated degradation
of SUMO-conjugates, but also led to a substantial increase in their
abundance (Figure 2A).
Degradation of SUMO-conjugates in general occurred less
rapidly than that of PML and its SUMO-modified isoforms in
both HFs and HepaRG cell types (Figure S3A). This suggests that
the identity of a given substrate, as well as the fact that it is
conjugated to SUMO species, influences the efficiency of ICP0-
mediated degradation. These data are consistent with the initial
localization of ICP0 to SUMO-conjugates localized at ND10 prior
to bringing about their degradation (Figures 2B and 2D, with
further details in Figures S4A and S4C). Interestingly, even in
PML-depleted cells, ICP0 colocalized with SUMO-2/3 conju-
gates, but not SUMO-1 conjugates, at the earliest stages of
infection when only very low levels of ICP0 were present
(Figures 2C, 2E, S4B and S4D). Therefore, ICP0 localizes to sites
that contain condensed SUMO-conjugates, either in the presence
or absence of PML. ICP0-mediated degradation of SUMO-
conjugates was also independent of PML expression (Figure S3B).
We conclude that ICP0 exhibits properties related to those of a
STUbL, inducing the rapid loss of SUMO-modified PML
followed by widespread proteasome-dependent degradation of
SUMO-conjugates during infection in a RING finger-dependent
manner.
ICP0 interacts with SUMO in a SIM-dependent manner
As ICP0 displayed STUbL-like properties, we next analyzed its
polypeptide sequence for the presence of SIMs and found seven
potential SIM-like sequences (SLS), six that conform to the
consensus (with the possible exceptions of SLS-2 and -6 that
Figure 2. ICP0 localizes to and induces the degradation of SUMO-1 and SUMO-2/3 conjugates during infection in a RING finger- and
proteasome-dependent manner. (A) HFs were infected at a MOI of 5 plaque forming units (pfu) per cell with wt HSV-1, ICP0-null (DICP0) or ICP0
RING finger deletion (DRING) mutant viruses in the absence or presence (-/+) of the proteasome inhibitor MG132. Cells were harvested at the
indicated time points post-infection (Hrs PI) and analyzed for SUMO-1 and SUMO-2/3 abundance. The blots were reprobed for viral antigens ICP0 and
UL42, and actin as a loading control. Longer exposures of western blots from duplicate experiments are shown in Figure S2B. (B–E) ICP0 localizes to
SUMO-2/3, but not SUMO-1, conjugates in a PML-independent manner. Control (shLuci) or PML-depleted (shPML) HFs were infected with wt HSV-1
and the localization of ICP0 (green) to endogenous SUMO-1 and SUMO-2/3 conjugates (red) was analyzed in cells at the periphery of developing
plaques (PML localization within these cells is shown in Figure S4). Nuclei were stained with DAPI. The insert at the lower right corner shows an
expanded region highlighted by the white box.
doi:10.1371/journal.ppat.1002245.g002
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contain proline residues), and one (SLS-4) that has homology
[IVISDS] to a SIM previously identified in hDaxx [38] and the
HCMV regulatory protein IE2 [39] (Figures 3A and 3B). These
predicted SLSs of ICP0 are distributed throughout the entire
ORF, with SLS-1 and -2 close to the RING finger, SLS-3 and -4
in the middle and SLS-5 to -7 in the C-terminal third of the
protein. SLS-4 lies adjacent to a known phospho-serine region
(Figure 3B) that is required for ND10 disruption in certain cell
types [40,41]. Comparison of ICP0 sequences from HSV-1 and
HSV-2 demonstrated that six of the predicted SIMs are conserved,
the exception being SLS-3 (Figure 3B).
Consistent with the presence of potential SIMs, yeast two-
hybrid (Y2H) assays demonstrated that ICP0 interacted with
both SUMO-2 and -3 (Figure 3C). ICP0 did not interact with
SUMO-1 in this assay system, even though SUMO-1 was
capable of interacting with hDaxx in a SIM-dependent manner
(Figure 3C and S5, [38]). USP7 was used as a positive control
for ICP0 interaction [42]. The ICP0-SUMO interaction was
Figure 3. ICP0 interacts with SUMO in a SIM-dependent manner. (A) Locations of predicted SIM-Like Sequences (SLS, black vertical bars), the
RING finger (grey box), nuclear localization sequence (nls, black horizontal bar), and USP7 binding domain (white box) within ICP0. Number arrows
refer to amino acid coordinates. (B) Alignment of SLS in HSV-1 and HSV-2 ICP0. Grey boxes highlight the hydrophobic core within individual SLSs. SLS-
4 is additionally aligned with SIMs of hDaxx and HCMV IE2. Square boxes adjacent to SLS-4 highlight phosphorylated serine residues. (C) Y2H analysis
showing ICP0 interaction with SUMO-2/3, but not SUMO-1, in a C-terminal di-glycine independent manner. Ubc9 and USP7 are positive controls for
SUMO and ICP0 interaction respectively. Mated diploids were plated out onto media lacking leucine and tryptophan (-L/-W, indicating the presence
of both plasmids) or leucine, tryptophan, and histidine (-L/-W/-H). Positive interactions are indicated by growth on medium lacking histidine. GAL4
activation domain (AD) or binding domain (BD) fusion orientations are highlighted. Vec indicates the respective empty vector control. (D) ICP0
interacts with SUMO-2/3 in a RING finger-independent manner and requires residues between amino acids 241 to 388. (E) Table highlighting residue
mutations made within SLS-4, -5 and -7. (F) Mutation of SLS-4 inhibits ICP0’s ability to interact with SUMO-2/3 in Y2H assay. (G) GST pull down assay
demonstrating that the C-terminal third of ICP0 (residues 594-775) interacts with SUMO-1.
doi:10.1371/journal.ppat.1002245.g003
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not mediated through covalent linkage, as SUMO-2/-3
mutants lacking the C-terminal di-glycine motif still interacted
with ICP0 (Figure 3C). Using a panel of C-terminal ICP0
deletion mutants we found that the SUMO-2/-3 interaction
occurred in an ICP0 RING finger-independent manner and
required residues 241-388 (Figure 3D). These data suggest that
either SLS-3 or SLS-4 could mediate the SUMO-2/-3
interaction. As SLS-3 is not conserved in HSV-2 (Figure 3B),
we investigated the requirement for SLS-4 and two other SIM-
like sequences (SLS-5 and -7) for interaction with SUMO in the
context of full-length ICP0. Mutation of SLS-4 abrogated the
SUMO-2/-3 interaction in the Y2H system, but mutation of
SLS-5 or -7, either individually or combined, had no effect
(Figures 3E and 3F). We conclude that SLS-4 constitutes a
genuine SIM that is specific for SUMO-2/3.
Given that the C-terminal third of ICP0 was shown to be
required for the efficient degradation of SUMO-conjugates during
infection (Figure S2C), in vitro pull-down assays were performed
using purified C-terminal fragments of ICP0 (residues 594-775
linked to GST) in order to determine if these sequences mediated
any interaction with SUMO (Figure 3G). In contrast to the Y2H
analysis (Figure 3F), the C-terminal fragment of ICP0 interacted
with SUMO-1, but not SUMO-2, in this assay. Individual
mutation of SLS-5, but not SLS-7, disrupted this interaction.
Surprisingly, the C-terminal region of ICP0 mutated in both SLS-
5 and SLS-7 interacted with SUMO-1 at wt levels. We conclude
from these data that the C-terminal portion of ICP0 is able to
interact with SUMO-1 and that SLS-5 probably represents an
authentic SIM for SUMO-1. However, further analysis will be
required in order to define the basis of ICP0-SUMO-1 interaction
within this region.
ICP0 ubiquitinates SUMO-2 chains in vitro and induces
the widespread degradation of SUMO-conjugates
The RING finger domain of ICP0 has E3 ubiquitin ligase
activity in vitro in the presence of the E2 ubiquitin conjugating
enzymes UbcH5a (UBE2D1) and UbcH6 (UBE2E1) [3,43].
Ubiquitination reactions carried in the presence of purified poly-
SUMO-2 chains demonstrated that ICP0 could catalyze the
formation of high MW poly-SUMO-2 ubiquitin conjugates in a
RING finger-dependent manner, which required sequences
encompassing SLS-4 (compare ICP0.1-323 with ICP0.1-396,
Figure 4A). Mutation of SLS-4 within the context of ICP0.1-396
significantly reduced ICP0’s ability to mediate the poly-ubiquiti-
nation of SUMO-2 chains in vitro (Figure 4A and B), even though
this mutant had ubiquitin ligase activity equivalent to that of full-
length ICP0 and ICP0.1-396 (Figure 4A, right-hand panels).
Taken together, these data indicate that ICP0 can directly interact
with and ubiquitinate poly-SUMO chains in solution and that
SLS-4 plays a role in this process. It is of interest to note that while
ICP0.1-396 can mediate the ubiquitination of poly-SUMO2
chains in vitro, this activity was reduced in comparison to full-
length ICP0 (Figure 4A and B), suggesting that additional
sequences and/or post-translational modifications may contribute
to ICP0’s ability to ubiquitinate poly-SUMO2 chains in solution.
To investigate the role of the SLSs within ICP0 in the
degradation of high MW SUMO-conjugates, inducible cell lines
expressing wt or SLS mutant forms of ICP0 were analyzed for
SUMO-conjugate abundance following doxycycline induction
(Figure 4C). Expression of both wt and mSLS-5/7 ICP0 resulted
in reduced levels of both SUMO-1 and SUMO-2/3 conjugates at
24 hours post-induction, whereas the mSLS-4 or mSLS-4/5/7
mutants did not. Analysis of PML stability demonstrated that wt,
Figure 4. SLS-4 is required for the in vitro ubiquitination of poly-SUMO-2 chains and degradation of SUMO conjugates in vivo. (A) In
vitro ubiquitination reactions were carried out in the presence of E1, UbcH5a and ubiquitin (Ubmix), poly-SUMO-2 chains and purified wt ICP0,
ICP0DRING, or ICP0 C-terminal truncation mutants ICP01-323, ICP01-396 or ICP01-396mSLS-4 as indicated (-/+). Ubiquitinated products were analyzed
by western blot for ubiquitinated SUMO species (left-) and poly-ubiquitin chain formation (right-hand panels, respectively). Poly-ubiquitinated SUMO-
2 species are labelled Poly-Ub-S2n. Superscripts denote the number of SUMO-2 (S2) molecules within the chain. (B) Quantification of Poly-Ub-S2n
species (dotted line) detected by western blot analysis in reaction mixtures containing ICP0, ICP01-396, and ICP01-396mSLS-4 expressed as a relative
fold decrease in relation to reaction mixtures containing wt ICP0. Error bars represent the standard deviation in Poly-Ub-S2n levels detected over four
independent experiments. (C) Analysis of SUMO conjugates and PML stability in cells induced to express wt ICP0, ICP0 mSLS-4, -5/7, -4/5/7 mutants,
or empty vector control (TetR) cells at 24 hours post-induction with doxycycline (Dox; +) compared to uninduced controls (-). The actin and ICP0 blots
provide loading and ICP0 expression controls.
doi:10.1371/journal.ppat.1002245.g004
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mSLS-4 and mSLS-5/7 forms of ICP0 could all induce the
substantial degradation of PML, whereas this was much less
marked in the case of the triple mutant ICP0-mSLS-4/5/7
(Figure 4C, an independent time course experiment is shown in
Figure S3C). In agreement with infection data (Figure S3A), these
results imply that ICP0 exhibits substrate selectivity with regard to
SUMO-conjugated species, in that PML is targeted more
efficiently than SUMO conjugates in general. Furthermore, since
the defect of the triple mutant in PML degradation is substantially
greater than either the single SLS-4 or the double SLS-5/7
mutations, it is possible that the SLSs are acting cooperatively.
Mutation of SLS-5 and -7 in the C-terminal region of ICP0 greatly
enhanced its accumulation after induction, and while the reasons
for this remain unknown, it could result in an underestimation of
any defects caused by these mutations. As an important control,
we found that all SLS mutant forms of ICP0 were able to induce
the formation of colocalizing conjugated ubiquitin (Figure S6),
indicating that these mutations did not compromise the E3
ubiquitin ligase activity of ICP0 per se. Collectively, the data in
Figures 3 and 4 indicate that ICP0 directly interacts with and
ubiquitinates SUMO, and combined mutations within SLS-4, -5,
and -7 reduce ICP0-dependent degradation of high MW SUMO
conjugates. We conclude that ICP0 has STUbL-like properties.
ICP0 induces the degradation of PML by both SUMO-
targeted and SUMO-independent mechanisms
We next tested whether ICP0 induces the degradation of PML
in a SUMO modification-dependent manner. PML is expressed as
a complex family of related isoforms that contain a SIM and
multiple SUMO modification sites [24,44,45] (Figure 5A). Using a
series of cell lines expressing individual EYFP-linked PML
isoforms in normal or PML-depleted backgrounds [46], we found
that the SUMO-modified forms of all PML isoforms were
degraded in an ICP0- and proteasome-dependent manner during
infection, consistent with previous studies analysing ICP0’s ability
to induce the degradation of endogenous PML during infection
[9–11]. In contrast, the unmodified forms of EYFP-PML were
relatively resistant to degradation, with the exception of PML
isoform I (Figure 5B). Individual EYFP-PML isoform degradation
was not dependent on endogenous PML as similar results were
obtained in PML-depleted cells (data not shown).
Using isoforms I and IV as example substrates, we investigated
the requirement for SUMO modification for ICP0 induced
degradation of PML. Lysine to arginine mutations at residues
160 and 490 (K160/490R), the two major SUMO modification
sites [47], were expressed in control and PML-depleted cells and
monitored for their respective stabilities during infection. In
contrast to PML.IV.K160/490R, PML.I.K160/490R was readily
degraded in an ICP0-dependent manner (Figures 5C and 5D).
Although the double K160/490R mutation substantially reduced
SUMO modification, some modified bands remained, particularly
in the presence of endogenous PML. Inclusion of the K65R
mutation (K65/160/490R), affecting the other published SUMO
modification site [47], did not alter this banding pattern [17]. We
noted that lysine 616 also falls within a good SUMO modification
consensus sequence (LKID). Additional mutation of K616R
(K160/490/616R), either in the presence or absence of the
K65R mutation, reduced modification to undetectable levels in
both endogenous and PML-depleted backgrounds (Figure 5E;
[17]). This mutant form of PML.I remained equally sensitive to
ICP0-mediated degradation (Figure 5E), indicating that sequences
specific to exon 9 within PML.I (Figure 5A), either directly or
indirectly, confer additional sensitivity to ICP0-mediated degra-
dation independent of PML SUMO modification status. These
data suggest that ICP0 utilizes dual targeting mechanisms to
mediate the degradation of PML during infection, one being a
SUMO-dependent mechanism that leads to the preferential
degradation of all SUMO-modified PML isoforms, and the other
a SUMO modification-independent mechanism that can target
PML.I for degradation via sequences encoded by exon 9.
SIM-like sequences within ICP0 contribute to its
biological functions
We next tested the hypothesis that SLSs within ICP0 contribute
to its ability to stimulate HSV-1 lytic infection and reactivation of
gene expression from quiescence. Cell lines that express various
mutants of ICP0 in an inducible manner were tested for their
ability to stimulate plaque formation of a HSV-1 ICP0-null
mutant virus and to reactivate gene expression from quiescent
HSV-1 genomes. The use of these assays to analyze other mutants
of ICP0 has been described in detail elsewhere [8]. N-terminal
fragments 1–240nls or 1–340nls had negligible complementation
activity in ICP0-null mutant virus plaque assays, whereas
fragments 1–374nls, 1–396nls and 1–594, that include SLS-4,
exhibited detectible levels of complementation activity (Figure 6B).
Mutation of SLS-4 within constructs 1–396nls and 1–594 virtually
eliminated complementation, indicating that SLS-4 contributes to
ICP0 activity in the context of these shorter fragments. Individual
mutation of SLS -4, -5 or -7 in full-length ICP0 had varying but
lesser effects on ICP0 complementation efficiency. However,
similar to PML degradation (Figure 4C and S3C), the triple
mutant was significantly less active than wt ICP0 (Figure 6B).
In assays monitoring the reactivation/derepression of b-
galactosidase gene expression from cells harbouring quiescent
HSV-1 genomes, large reductions in activity resulted from
mutation of SLS-4 in the 1-396nls and 1–594 backgrounds, again
highlighting the importance of SLS-4 in the context of these
shorter ICP0 fragments (Figure 6C). Comparison of the effects of
individual and combined SLS mutants in the full-length ICP0
again demonstrated varying levels of activity, with the triple SLS
mutant being the most defective with over a 50% drop in
reactivation efficiency (Figure 6C). We have observed that mutant
ICP0 proteins frequently retain greater relative activity in this
reactivation assay than in the complementation assay [8,48]. We
conclude that SIM-like sequences within ICP0 significantly
contribute to its biological functions, both in its ability to
complement ICP0-null mutant plaque formation and, to a lesser
extent, the reactivation of quiescent HSV-1 gene expression.
However, it is likely that additional sequences within the C-
terminal third of ICP0 also contribute to its functionality in these
assay systems.
ICP0 and its viral orthologues induce the proteasome-
dependent degradation of SUMO conjugates
independent of infection
We have shown that related RING finger viral orthologues of
ICP0, including BICP0 (from bovine herpes virus type 1), EICP0
(from equine herpes virus type 1), and PICP0 (from pseudorabies
virus), have E3 ubiquitin ligase activity in vitro and can partially
substitute the functional requirement for ICP0 during HSV-1
ICP0-null mutant infection [48]. Importantly, these viral ortho-
logues were shown not only to inhibit the recruitment of PML to
sites associated with incoming HSV-1 viral genomes, but also to
modulate the SUMO conjugation profile of PML and/or Sp100
[48]. We therefore investigated whether STUbL-like properties
were a conserved activity of the ICP0 family of RING finger
proteins.
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All ICP0 viral orthologues, including VICP0 from varicella
zoster virus, contain multiple putative SIM-like sequences, with at
least one SLS conforming to the SIM consensus (Figure 7A and 7B
bold highlights, [49]). SLS-3 of BICP0 also shares homology
(Figure 7B, solid box) with the phospho-serine region downstream
of SLS-4 of ICP0 (IVISDS, Figure 3B). We note that the other
viral orthologues also contain similar acidic and/or serine amino
acid sequences following some of their putative SIM-like sequences
(Figure 7B, dashed boxes). These negatively charged motifs are
similar to other examples that have been shown to enhance SIM-
SUMO interactions [27,28,50].
Utilizing inducible cell lines that express ICP0 or related viral
proteins, we found that like ICP0 (Figure 4C), BICP0, EICP0, and
PICP0 were all capable of reducing the overall abundance of high
MW SUMO conjugates following doxycycline induction
(Figure 7C and S7). As found previously [48], VICP0 was
expressed at insufficient levels to be active in this experimental
system (Figure S7). Ubc9 levels remained unaltered in cells
Figure 5. ICP0 preferentially induces the degradation of SUMO-conjugated PML. (A) Maps of PML.I and PML.IV depicting RING, B-box,
coiled-coil and nls motifs. Arrows indicate the SIM and lysine (K) residues mutated in this study, vertical lines show exon boundaries in PML.I, and the
black horizontal bar represents the PML.IV specific exon 8b. (B) ICP0 preferentially induces the proteasome-dependent degradation of SUMO-
modified forms of PML.I-VI. Cells expressing EYFP-PML isoforms I-VI were infected with wt (MOI 2) or ICP0-null mutant HSV-1 (DICP0, MOI 10), in the
presence or absence of MG132, and harvested at 6 hours post-infection. Cell extracts were analyzed by western blot for EYFP-PML in comparison with
mock-infected controls. (C and D) ICP0 degrades EYFP-PML.I but not EYFP-PML.IV K160/490R mutants in both control cells (C) and cells depleted of
endogenous PML (D). (E) ICP0 induces the degradation of EYFP-PML.I.K65/160/490/616R in a SUMO modification-independent manner.
doi:10.1371/journal.ppat.1002245.g005
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expressing ICP0 or related viral orthologues (Figure 7C), indicat-
ing that the degradation of SUMO conjugates could not be
explained by indirect degradation of Ubc9. We conclude that the
induced loss of SUMO conjugates by ICP0 and its viral
orthologues occurs independently of viral infection and that
STUbL-like activity is a conserved property of these related viral
RING finger ubiquitin ligases.
Discussion
In this report we demonstrate that the viral ubiquitin ligase
ICP0 has STUbL-like properties that contribute to its ability to
counteract host-cell intrinsic resistance to HSV-1 infection.
Intrinsic resistance represents the first line of intracellular antiviral
defence and, unlike innate or acquired antiviral immunity, is
mediated by pre-existing cellular factors that attempt to restrict
viral replication during the initial stages of infection (for reviews
see [14,51,52]). In the case of herpesviruses, intrinsic resistance
leads to the repression of viral gene expression, which may reflect
an important biological aspect of how these viruses attain a
quiescent state of infection prior to the establishment of latency.
Whilst the role of chromatin modification on viral gene
transcription has been investigated in many laboratories, we have
identified an additional aspect to intrinsic resistance (not
necessarily unconnected) that involves the SUMO conjugation
pathway and components of ND10 [12,13,15,16,31].
We have recently shown that recruitment of PML and hDaxx to
foci associated with incoming viral genomes is dependent upon
their SIMs, and that additional SUMO-2/3 conjugates, as well as
the SUMO E3 ligase PIAS2b, are also recruited to viral genomes
in a PML-independent manner [17]. Consistent with these
observations, we show here that depletion of Ubc9, the sole
SUMO E2 conjugating enzyme, restricts the cell’s ability to
repress ICP0-null mutant virus replication (Figure 1C and 1D) and
inhibits the recruitment of SUMO conjugates and PML to foci
associated with incoming viral genomes (Figure S1). Collectively
these data demonstrate that the SUMO conjugation pathway
plays a role in intrinsic resistance to HSV-1 infection. This
phenotype is consistent with previously documented roles for
SUMO conjugation in transcriptional repression (reviewed in
[53]), the assembly of ND10 [38,44], and the recruitment of
chromatin modifying enzymes into ND10 [54]. It is therefore
likely that in the context of intrinsic antiviral defence this pathway
is involved in the assembly of a network of repressive factors that
associate with viral genomes following their entry into the cell
nucleus in order to bring about repression of viral transcription
(summarized in Figure 8).
Analogous to viral counter measures against innate and
acquired immunity, viruses have evolved mechanisms to disarm
intrinsic antiviral defence. One of the first proteins to be expressed
during HSV-1 infection is ICP0, a viral RING finger ubiquitin
ligase that localizes to and disrupts ND10 by mediating the
degradation of PML, its SUMO-modified isoforms, and SUMO-
modified Sp100 [9–11]. The degradation and dispersal of ND10
constituent proteins correlates well with ICP0’s ability to
counteract intrinsic defence, thereby aiding the efficient initiation
Figure 6. SLSs within ICP0 regulate its ability to complement and reactivate mutant HSV-1 viruses in cell culture. (A) As in Figure 3A.
(B) Complementation of ICP0-null mutant HSV-1 plaque formation by prior induction of expression of various N-terminal fragments of ICP0 (as
depicted in A) and full-length ICP0 carrying individual or combined SLS mutations in the inducible cell line system. The titre of a mutant virus stock
was determined in each cell line and plotted with respect to that in cells expressing wt ICP0. Means and standard deviations of two to seven
independent determinations are presented. (C) Analysis of ICP0 induced reactivation of gene expression from quiescent HSV-1 genomes. Cells were
infected with multiply defective HSV-1 mutant in1374 to establish quiescently infected cultures, then 24 h later ICP0 expression was induced with
doxycycline. Reactivation was assessed the following day by staining for b-galactosidase expression from the marker gene in the in1374 genome. The
proportion of reactivated cells in each cell line was expressed as a percentage of that in cells expressing wt ICP0 following determination of positive
cell numbers in three high magnification views of each sample. Means and standard deviations are presented.
doi:10.1371/journal.ppat.1002245.g006
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of viral replication. However, the precise mechanism(s) by which
ICP0 targets these ND10 proteins for degradation has remained
elusive. Given the parallels between ICP0 and the cellular STUbL
RNF4 [22,23,29], we decided to investigate if ICP0 possessed
STUbL-like properties that contribute to its ability to counteract
intrinsic defence. Whilst we show that ICP0 shares some
phenotypic similarities to RNF4, a number of important
differences have also been highlighted. Like RNF4, ICP0
preferentially induces the degradation of SUMO-modified forms
of PML, but unlike RNF4 [23,30], ICP0 is able to target PML
without the need for additional PML SUMO modification
(Figures 5B and S3A). In addition, ICP0 also induces the
widespread degradation of SUMO-1 and SUMO-2/3 conjugate
proteins during infection (Figure 2A and S2B). Importantly, this
activity is not dependent upon the presence of PML (Figure S3B),
indicating that this phenotype is not an indirect consequence of
ND10 disruption. These data demonstrate that ICP0 targets
additional SUMO-modified proteins for degradation other than
those constitutively modified at ND10, consistent with its ability to
localize to SUMO-2/3 conjugates in PML-depleted cells during
the initial stages of infection (Figure 2E). These differences, plus
others described below, indicate that ICP0 does not represent a
precise viral orthologue of RNF4.
Although ICP0 contains many SIM-like sequences, only one of
these was strongly identified as a functional SIM (SLS-4, IVISDS).
This motif shares homology to previously characterized SIMs
within hDaxx and the HCMV IE2 protein (Figure 3B; [38,39]).
SLS-4 is required for ICP0’s ability to interact with SUMO-2
(Figure 3F), ubiquitinate poly-SUMO-2 chains in vitro (Figure 4A),
and to reduce the level of SUMO conjugates when expressed by
itself in an inducible cell line system (Figure 4C). These data
support the hypothesis that ICP0 has STUbL-like activity. It is of
interest to note that serine residues adjacent to SLS-4 can be
phosphorylated [41] and are required for ICP0’s ability to disperse
PML in transfection based assays in certain cell types [40]. It is
plausible therefore that this particular SIM is regulated by
phosphorylation, similar to those previously identified in SUMO
ligases [27]. Whilst the extent to which the other SIM-like
sequences contribute to SUMO interaction remains unclear, our
data indicate that the C-terminal third of ICP0 can additionally
interact with SUMO-1, potentially in a SLS-5 dependent manner
(Figure 3G). However, we note that this region influences many
aspects of ICP0 function, including USP7 and CoREST binding
[42,55], ICP0 multimerization and ND10 localization [56].
Whilst ICP0’s STUbL-like activity is important for its biological
functions (Figures 6B and 6C), it is important to note that ICP0
also directly interacts with and ubiquitinates other cellular proteins
such as RNF8, USP7 and p53 in a SUMO modification-
independent manner [43,57,58]. Here we found that PML.I can
also be targeted for degradation in a SUMO modification-
independent manner (Figures 5B–E). Thus, ICP0 clearly has both
SUMO-dependent and -independent targeting specificities that
may have an overall accumulative effect on counteracting intrinsic
antiviral resistance. Furthermore, since SUMO-modified PML is
degraded more rapidly than the bulk of SUMO conjugates, it
appears that the identity of a SUMO-modified protein also
influences ICP0 substrate targeting. Indeed, it is possible that
optimal ICP0 targeting involves both SUMO- and substrate-
dependent interactions that synergize to define the most avid ICP0
targets. Another important consideration is the distinction between
Figure 7. ICP0 and its viral orthologues induce the degradation
of SUMO conjugates independently of virus infection and the
degradation of Ubc9. (A) Schematic representation of ICP0
orthologue proteins BICP0, EICP0, VICP0 and PICP0 illustrating the
distribution of putative SIM-Like Sequence (SLS) motifs in relation to
their respective RING finger domains (grey boxes). Numbering reflects
the first and last amino acid within each ORF. (B) Amino acid sequence
of putative SLS motifs identified within each ICP0 viral orthologue.
Numbers refer to the coordinates of the first amino acid shown within
each SLS with respect to their individual ORF sequence. Bold lettering
represents motifs that conform to the SIM consensus as described [24–
26]. Boxed sequences show conserved triplets composed of serine or
acidic residues. (C) Cell lines induced to express ICP0, myc-tagged viral
orthologues (BICP0, EICP0 and PICP0), or control cells (TetR) were
analyzed for Ubc9 expression levels in relation to SUMO conjugate
abundance 24 hours after treatment with doxycycline (0.1 mg/ml) (2/+).
Blots were reprobed for ICP0, myc-tagged orthologue expression, and
tubulin as a loading control.
doi:10.1371/journal.ppat.1002245.g007
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biochemical targeting and spatial localization. SUMO-modified
PML may be degraded more rapidly than other SUMO
conjugates because ICP0 interacts more avidly with the former
than the latter, or because the high concentration of ICP0 within
ND10 preferentially enhances degradation of SUMO conjugates
within these structures. While these two factors may well be
related, we note that ICP0 colocalizes with SUMO-2/3 conjugates
even in the absence of PML (Figure 2E). Similarly, the reduced
activity of the C-terminal deletion mutant ICP0.1-594 on both
PML [9] and SUMO conjugates (Figure S2C) could be due to less
efficient biochemical targeting at a molecular level (Figure 3G), or
because this mutant is diffusely distributed in the nucleus and not
spatially targeted to ND10 where intra-nuclear SUMO conjugates
accumulate.
Viruses have evolved numerous mechanisms to exploit ubiquitin
conjugation in order to create cellular environments that favour
viral replication. Our data identify a dual targeting (SUMO- and
substrate-dependent) mechanism through which ICP0 manipu-
lates the cellular environment in favour of HSV-1 replication.
Given that the STUbL-like properties of ICP0 appear to be a
conserved activity of this family of viral RING finger ubiquitin
ligases (Figure 7C), it would be interesting to determine if this is a
common mechanism for substrate targeting utilized by other viral
ubiquitin ligases. The observation that ICP0 targets SUMO-
conjugated proteins in general for proteasome-mediated degrada-
tion provides a plausible explanation for its ability to inhibit
multiple factors involved in intrinsic antiviral defence (summarized
in Figure 8). This activity may also account for other proposed
roles for ICP0 in regulating other cellular pathways, including
innate interferon-mediated defence and DNA damage response
pathways, as components of these pathways have been shown to
be regulated by SUMO modification [59,60,61,62]. We stress,
however, that the target specificity of ICP0 is regulated by factors
in addition to the presence of conjugated SUMO, and that the
Figure 8. Model depicting the regulation of intrinsic antiviral resistance to HSV-1 infection mediated by the SUMO conjugation
pathway. (1) During the initial stages of HSV-1 infection viral genomes enter the nucleus of infected cells. (2) Major ND10 components including
PML, Sp100, hDaxx, and ATRX are recruited into foci that are closely associated with incoming HSV-1 genomes. This recruitment is dependent upon
the SUMO conjugation pathway (Figures 1 and S1) and SIMs within PML, Sp100 and hDaxx [17]. (3) During wt HSV-1 infection, the STUbL-like activity
of ICP0 promotes the preferential degradation of SUMO-conjugated proteins leading to the dispersal of restriction factors and the efficient onset of
viral replication. (4) In the absence of ICP0, specific SUMO-conjugated proteins mediate the transcriptional repression of viral gene expression leading
to the establishment of viral quiescence and latency.
doi:10.1371/journal.ppat.1002245.g008
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biologically relevant targets will comprise only a minority of total
SUMO-conjugated proteins. Nonetheless, our observations sug-
gest a more general role for SUMO conjugation in resistance to
pathogen infection. Evidence in support of this hypothesis
includes: (i) that the chicken adenovirus protein Gam-1 inactivates
the SUMO conjugation pathway by targeting the SUMO E1
activating enzyme complex in order to stimulate viral transcription
[63]; (ii) that a pathogenic bacterium impairs the SUMO
modification pathway to enhance infection [64]; and (iii) that
SUMO modification of transcriptional regulatory proteins is
frequently associated with transcriptional repression [53]. Since
the recruitment of ND10 components to sites associated with viral
genomes occurs extremely quickly and is independent of viral
transcription [16], we propose that the SUMO pathway may
regulate a process that responds to the entry of foreign DNA in
general into the cell nucleus. Further investigation into ICP0’s
SUMO-targeted and SUMO-independent ubiquitin ligase activ-
ities will provide insight into the cellular processes that regulate
this response to infectious pathogens.
Materials and Methods
Cells
Human foetal foreskin diploid fibroblasts (HFs) were grown in
Dulbeccos Modified Eagles Medium with 10% fetal calf serum
(FCS). HepaRG cells [65] were grown in Williams Medium E with
10% fetal bovine serum Gold (PAA Laboratories Ltd), 2 mM
glutamine, 5 mg/ml insulin and 0.5 mM hydrocortisone. All cell
growth media contained 100 units/ml penicillin and 100 mg/ml
streptomycin. PML-depleted and control HepaRG and HFs cells
were described previously [12,13]. Control and PML-depleted
HepaRG cells reconstituted with individual PML isoforms
expressed at close to endogenous levels and derivatives expressing
PML isoforms I and IV with lysine to arginine substitutions at the
known SUMO modification sites and at lysine residue 616 have
been described previously [46]. PML isoforms are named
according to [45]. Tetracycline inducible HepRG cells expressing
ICP0 or alpha herpes viral orthologues have also been described
previously [48]. Ubc9-depleted cells were constructed by lentiviral
transduction, as described in [13] expressing a shRNA based upon
a 19-mer (5’ GAAGTTTGCGCCCTCATAA 3’) within the Ubc9
open reading frame.
HSV-1 strains and plaque assays
Wild type HSV-1 strain 17syn+, its ICP0-null mutant derivative
dl1403 [66], RING finger deletion mutant FXE [67], and C-
terminal truncation mutant E52 (expressing ICP0.1-594 [56]) were
grown and titrated as previously described [68]. Derivatives of wt
(in1863) and ICP0-null mutant (dl1403/CMVlacZ) HSV-1 that
contain a b-galactosidase gene linked to the human cytomegalo-
virus immediate-early promoter/enhancer inserted into the tk
locus were used for plaque assays as described [12].
Western blot analysis and antibodies
Cells in 24-well dishes at 16105 cells per well were washed with
phosphate buffered saline before harvesting in SDS-PAGE loading
buffer. Proteins were resolved by SDS-PAGE and transferred to
nitrocellulose membranes for western blotting. Monoclonal
antibodies utilized recognised the following proteins: actin (AC-
40, Sigma-Aldrich), tubulin (T4026, Sigma-Aldrich), ubiquitin
(P4D1, Santa Cruz), ICP0 (11060, [69], UL42 [70], ICP4 (58S,
[71], myc (9E10 sc-40, Santa Cruz) and PML 5E10 [72]. Rabbit
polyclonal antibodies were used to detect Sp100 (SpGH [73]),
PML (sc-9863, Santa Cruz), Ubc9 (ab30505, AbCam); EGFP
(ab290, Abcam), SUMO-1 (ab32058, Abcam), and SUMO-2/3
(ab3742, Abcam).
Immunofluorescence and confocal microscopy
Cells on 13 mm glass coverslips were fixed and permeabilized
using 2.5% non-buffered formaldehyde and 0.5% Triton-X100 in
10 mM HEPES (pH 7.0), 100 mM NaCl, 300 mM sucrose,
3 mM MgCl2, 5 mM EGTA. The secondary antibodies used
were Alexa 488, 594, and 633 conjugated donkey anti-rabbit,
- sheep, and -mouse IgG (Invitrogen). A glycerol-based mounting
medium was used (Citifluor AF1). The samples were examined
using a Zeiss LSM 510 confocal microscope with 488 nm, 543 nm
and 633 nm laser lines and a x63 Plan-Apochromat oil immersion
lens, NA 1.40. Exported images were processed using Adobe
Photoshop with minimal adjustment and assembled for presenta-
tion using Adobe Illustrator.
Yeast-two hybrid (Y2H) analysis
Y2H analysis was based upon the Matchmaker 3 system
(Clontech) using AH109 and Y187 yeast strains. ICP0 cDNAs
encoding wt ICP0.1–775, ICP0.1–775DRING (FXE), ICP0.1–388
and 1–241, along with hDaxx and hDaxx.mSIM (C-terminal SIM
mutant aa 733–740 IIVLSDSD to IGAGSDSD, [17]) were cloned
into pGAD-T7 in frame with the GAL4 activation domain (AD).
cDNAs encoding SUMO isoforms, their inactive conjugation
mutants (-GG to -AA), pp71 and USP7 were cloned into pGBK-
T7 in frame with the GAL4 DNA binding domain (BD).
Transformed yeast colonies were picked, mated overnight, and
diploids serially diluted prior to plating out onto selective medium
(as highlighted) following the manufacturer’s guidelines. Colonies
were allowed to grow for 72 hours prior to image capture.
Protein purification and in vitro assays
Full-length poly-histidine tagged ICP0 and ICP0DRING were
purified as previously described [3]. Poly-histidine tagged ICP0.1–
323, ICP0.1–396, ICP0.1–396SLS-4, SUMO-1 and SUMO-2
were purified from bacterial extracts utilizing Nickel agarose
affinity chromatography and dialysed into 50 mM Tris (pH 7.5),
150 mM NaCl, 2.5% glycerol, 2 mM MgCl2, 1 mM DTT. Poly-
HisSUMO-2 chains were purchased from Boston Biochem. In vitro
ubiquitination reactions were carried out in the presence of 20 ng
poly-HisSUMO-2 chains as essentially described in [43] utilizing
10 ng E1 activating enzyme, 30 ng UbcH5a, 2.5 mg ubiquitin
(Sigma-Aldrich), and 100 ng ICP0, ICP0DRING, ICP0.1–323, or
ICP0.1.396 in the presence of 50 mM Tris (pH 7.5), 50 mM
NaCl, 1 mM MgCl2 and 5 mM ATP. Reactions were carried out
at 37uC for 90 minutes and terminated by the addition of boiling
mix containing 8 M urea and 100 mM DTT. Quantification of
poly-ubiquitinated poly-SUMO2 chains was performed by
densitometry analysis of western blots using Quantity One
software (Bio-Rad).
Interaction analysis
Glutathione-S-Transferase (GST) pull-downs were carried out
in buffer H (50 mM HEPES pH 7.0, 150 mM NaCl, 5 mM b-
mercaptoethanol and 0.1% NP-40) using beads bound to either
GST alone or GST linked to the C-terminal 594-775 amino acids
of ICP0 (GST-E52; [56]) or equivalent fragments with mutations
in SLS-5, -7, or -5/7 in 1.5 ml of precleared bacterial supernatants
containing either His-tagged SUMO-1 or SUMO-2 for 90
minutes end-over-end at 4uC. The beads were washed three times
in 1 ml buffer H and soluble complexes were eluted in 60 ml of 1x
SDS-PAGE loading buffer.
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ICP0 inducible cells lines
HepaRG cells expressing wt and 1–594 C-terminal truncation
mutant ICP0 proteins in an inducible manner have been
described previously [8]. A series of C-terminal truncation
mutants of ICP0 were constructed using existing restriction sites
or previously described EcoRI linker insertion mutants [5] as
follows: ICP0.396nls and ICP0.1–517 used the NotI or MluI sites
in the ICP0 cDNA; ICP0.1–547, 1–374nls and 1–340nls used
linker insertions E1, E51 and E15; ICP0.1–241nls used the ICP0
truncation fragment including the first 241 codons described
previously [3]. ICP0.1–547 and ICP0.1–517 include the normal
ICP0 nuclear localization signal and the constructs include a C-
terminal linker containing stop codons. The shorter truncation
mutants (with nls in the name) contain a C-terminal linker
encoding the SV40 T-antigen nuclear localization signal followed
by a stop codon. Substitution mutants in SLS-5 (VVAL to
GGAL) and SLS-7 (VVLV to GGLV) were constructed by a
PCR splicing approach. MluI-SalI fragments containing the
desired mutations were transferred into the wt ICP0 lentivirus
expression vector. Substitution mutants in SLS-4 (PIVI to PGAG)
were constructed by oligonucleotide synthesis of the region
between the SfiI and NotI sites in the ICP0 cDNA, maintaining
the coding potential except for the desired mutations, while
decreasing the GC content by introduction of silent mutations,
then rebuilding the oligonucleotides into the wt cDNA. The
double mutant mSLS-5/7 was prepared by serial mutagenesis.
The mSLS-4 mutants in the 1-594 and 1-396nls truncations and
the mSLS-5/7 double mutant were constructed using the NotI
site on the 3’ side of the mutated SLS-4 motif. All mutants were
confirmed by extensive DNA sequence analysis after insertion
into lentiviral vectors. Cell lines expressing these proteins were
isolated as described previously [8]. Assays of complementation of
plaque formation by ICP0-null mutant HSV-1 and derepression
of quiescent HSV-1 after induction of ICP0 expression were
performed and quantified as described [8].
Supporting Information
Figure S1 Ubc9 expression is required for the efficient
recruitment of SUMO and PML to sites associated with incoming
HSV-1 genomes in the absence of ICP0. Control (shNeg) or
Ubc9-depleted (shUbc9) HFs were infected with an ICP0-null
mutant virus (DICP0) and the recruitment of SUMO-1, SUMO-
2/3, and PML proteins (green) to sites associated with incoming
viral genomes (as shown by ICP4 staining, red) was analyzed in
cells at the periphery of developing plaques. Scale bar represents
5 mm.
(EPS)
Figure S2 The C-terminal third of ICP0 is required for the
efficient degradation of high MW SUMO conjugates during
HSV-1 infection. (A) As in Figure 3A. (B) Western blots of HFs
infected with wt or ICP0-null (DICP0) mutant HSV-1 at MOI of
5 pfu per cell in the absence or presence (2/+) of MG132 and
harvested at the indicated times post-infection (Hrs PI). Other
details are as described in Figure 2. (C) Analysis of SUMO
conjugate abundance in HFs infected with wt or C-terminal ICP0
truncation mutant (ICP0.1–594) infected at various MOI at
8 hours PI.
(EPS)
Figure S3 ICP0 induces the proteasome-dependent degrada-
tion of SUMO conjugates in a PML-independent manner. (A)
HFs and HepaRG cells were infected with wt HSV-1 at an MOI
of 2 pfu per cell and harvested at the indicated times post-
infection (Hrs PI). The abundance of SUMO conjugates and
PML was analyzed. ICP0 and actin provide the infection and
loading controls, respectively. (B) Control (shLuci) or PML-
depleted (shPML) HFs were infected with wt HSV-1 or ICP0-null
(DICP0) mutant virus at an MOI of 5 pfu per cell in the absence
or presence (2/+) of MG132. Cells were harvested at the
indicated times post-infection (Hrs PI) and analyzed for SUMO-1
and SUMO-2/3 conjugate abundance. Blots were reprobed for
viral antigens ICP0, ICP4 and UL42, and tubulin as a loading
control. (C) Time course analyzing PML stability in cells induced
to express wt ICP0 or ICP0 mSLS-4, 25/7, 24/5/7 mutants at
various time points post-induction (hours) with doxycycline
(0.1 mg/ml Dox). The actin and ICP0 blots provide loading
and ICP0 expression controls.
(EPS)
Figure S4 ICP0 localizes to SUMO-2/3 conjugates in a PML-
independent manner during the early stages of HSV-1 infection.
(A–D) The separated channels of the images from Figures 2B-E,
including the channel for PML as a control for PML depletion,
showing the relative localization of ICP0 (green), SUMO
conjugates (red), and PML (cyan) in control (shLuci) and PML-
depleted (shPML) cells at the periphery of developing plaques at
early times post-infection with wt HSV-1. Nuclei were stained with
DAPI. The insert at the lower right corner shows an expanded
region highlighted by the white box.
(EPS)
Figure S5 SUMO-1 interactions with hDaxx, but not ICP0, in a
SIM-SUMO dependent manner in the yeast-two-hybrid system.
Mated diploids expression fusion proteins of interest (as highlight-
ed) were plated on to selective media (as described in Figure 3C)
either in the presence or absence of 1 mM 3-aminotriazole (3-AT).
GAL4 activation domain (AD) or binding domain (BD) fusion
domain orientations are indicated. Vec indicates the empty vector
control. USP7 and pp71, known binding partners of ICP0 and
hDaxx respectively [42,74], were used as positive controls for
interaction. Wt hDaxx and hDaxx.mSIM, a C-terminal SIM
mutant (aa 733–740 IIVLSDSD to IGAGSDSD) was used as a
control for SIM-SUMO-1 interaction.
(EPS)
Figure S6 ICP0 SLS mutants induce the colocalization of
conjugated ubiquitin within cell nuclei. Cells were induced to
express wt ICP0, ICP0 mSLS-4, -5/7, or -4/5/7 (green) and
analyzed for their respective abilities to colocalize with conjugated
ubiquitin (conj. Ub, red) as detected by FK2 staining by confocal
microscopy. Scale represents 5 mm.
(EPS)
Figure S7 ICP0 and its viral orthologues induce the degradation
of both SUMO-1 and SUMO-2 conjugates independently of virus
infection. Cell lines induced to express ICP0, myc-tagged viral
orthologues (BICP0, EICP0, PICP0 and VICP0), or control cells
(TetR) were analyzed for SUMO-1 and SUMO-2/-3 conjugate
abundance 24 hours after treatment with doxycycline (0.1 mg/ml;
2/+). Blots were reprobed for ICP0, myc-tagged orthologue
expression, and actin as a loading control.
(EPS)
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